Q-Line Biotech NSE SME IPO review

The company is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables.
It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments.
As the company has no listed peers, it is trying to extract fancy price for its IPO.
Based on its overall financial data, the issue appears fully priced.
Well-informed investors may park moderate funds for long term.

About Company

Q-Line Biotech Ltd. (QBL) is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs since 2013 directly or through its distributor/s majorly to diagnostic service providers, hospitals and medical colleges.

The company has established its brands over a period of 12 years through its experience, R & D, manufacturing capabilities and quality assurance. The core segments of operations of the Company in IVD Industry include Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids).

QBL’s key manufacturing segments include indigenous manufacturing of reagents including Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids) and supplying/ manufacturing of in-vitro diagnostics (IVD), Pathology equipment’s & devices. Further during the Covid-19 pandemic, the company diversified its focus and with the technical collaboration of third-party institutes and through its own R&D team developed a range of Covid testing kits viz. RT-PCR Kits, RNA Extraction Kits, VTM Kits etc.

It is research driven company engaged in developing and manufacturing a wide range of reagents formulations used across various IVD and diagnostic needs. The company leverages its R&D capabilities to develop and manufacture a portfolio of differentiated reagent formulations /products. Further, for its certain Class of Reagent & equipment’s and devices manufacturing business, the company has entered into technical collaboration with certain international companies. Under the agreement terms, it undertakes the manufacturing of these Reagent and equipment’s and devices as per the technical collaboration and specifications provided by the partners or companies.

With the help of these collaborations the equipment and devices adhere to strict quality control, international standards and certifications. As of March 31, 2026, the company employed 19 personnel at R&D laboratories, which constituted 5.25% of its total permanent employee strength. As of March 31, 2026, it had 362 employees on its payroll and additional 223 contract employees in various departments.

Issue Details / Capital History

The company is coming out with its maiden book building route IPO of 6253200 equity shares of Rs. 10 each to mobilize Rs. 214.48 cr. at the upper cap. The company has announced a price band of Rs. 326 - Rs. 343 per share. The minimum application to be made is for 800 shares and in multiples of 400 shares thereon, thereafter. The IPO opens for subscription on May 21, 2026, and will close on May 25, 2026. The IPO constitute 26.81% of the post-IPO paid-up capital of the company. The shares will be listed on NSE SME Emerge. From the net proceeds of the IPO, it will utilize Rs. 93.50 cr. for working capital, Rs. 90.00 cr. for repayment/prepayment of certain borrowings, and the rest for general corporate purposes.

The company raised Rs. 27.44 cr. in a pre-IPO placement of 800000 shares in May 2026, at Rs. 343 per share.

The IPO is jointly lead managed by Hem Securities Ltd., and Share India Capital Services Pvt. Ltd., Purva Sharegistry (India) Pvt. Ltd., is the registrar to the issue. HEM group’s Hem Finlease Pvt. Ltd., is the market maker as well as a syndicate member.

The company has issued initial equity capital at par value. It raised further equity shares in the price range of Rs. 125 – Rs. 417 between March 2019 and May 2026. It has also issued bonus shares in the ratio of 2 for 1 in March 2016, and 9 for 1 in August 2025. The average cost of acquisition of shares by the promoters is Rs. 0.00, Rs. 0.04, and Rs. 18.34 per share.

Post-IPO, company’s current paid-up equity capital of Rs. 17.07 cr. will stand enhanced to Rs. 23.33 cr. Based on the upper band of the IPO pricing, the company is looking for a market cap of Rs. 800.16 cr.

IPO Lead Managers & Registrar

Financial Performance

On the financial performance front, for the last three fiscals, the company has (on a consolidated basis) posted total income/ net profit, of Rs. 184.81 cr. / Rs. 32.10 cr. (FY23), Rs. 206.45 cr. / Rs. 34.44 cr. (FY24), Rs. 322.58 cr. / Rs. 28.13 cr. (FY25). For 9M of FY26 ended on December 31, 2025, it earned a net profit of Rs. 38.69 cr. on a total income of Rs. 236.50 cr. Though it posted growth in its top lines for the reported periods, its bottom line posted inconsistency. For FY25, it posted lower net profit of Rs. 28.13 cr., and for 9M-FY26, though the top line is Rs, 236.50 cr. it posted bumper profit of Rs. 38.69 cr. in a pre-IPO period, that not only raise eyebrows, but also concern over its sustainability going forward. Despite higher other income for FY25, it marked lower net following extra-ordinary item of Rs. 16.97 cr. Its contingent liability stood at Rs. 61.64 cr. as of December 31, 2025, that raises alarm. Its overall borrowings of Rs. 242.57 cr. as of December 31, 2025, raise concern.

For the last two fiscals, the company has reported an average EPS of Rs. 25.00, and an average RoNW of 23.17%. The issue is priced at a P/BV of 2.44 based on its NAV of Rs. 140.81 per share as of December 31, 2025, but its post-IPO NAV data is missing from the offer documents.

If we attribute FY26 super earnings to its post-IPO fully diluted paid-up equity capital, then the asking price is at a P/E of 15.51, and based on FY25 earnings, the P/E stands at 28.44. The issue appears fully priced, based on its bumper earnings for 9M-FY26, which may not be sustained.

For the reported periods, the company has posted PAT margins of 17.56% (FY23), 16.92% (FY24), 8.97% (FY25), 16.65% (9M-FY26), and RoCE margins of 22.14%, 19.25%, 17.66%, 13.32%, respectively, for referred periods.

All amounts in Indian Rupees crores

Period Ended	Revenue	Expense	PAT	Assets
2023	₹184.81	₹154.97	₹32.10	₹251.58
2024	₹206.45	₹175.85	₹34.44	₹339.25
2025	₹322.58	₹261.43	₹28.13	₹455.49
Dec 2025	₹236.50	₹186.96	₹38.69	₹561.34

Dividend Policy

The company has not paid any dividends for the reported periods of the offer document. It will adopt a prudent dividend policy, based on its financial performance and future prospects.

Comparison with Listed Peers - for Fiscal 2025

As per the offer document, the company has no listed peers to compare with.

Name of the Company	Face Value (₹)	EPS basic (₹)	EPS Diluted (₹)	RONW (%)	P/E Ratio	NAV (₹)
Powerica Limited	5	15.26	15.26	15.37 %	24.45	99.76
Listed Peers
Cummins India Limited	2	72.15	72.15	26.45%	64.13	272.78
Kirloskar Oil Engines Limited	2	33.71	33.60	15.85%	43.24	212.60
NTPC Green Energy Limited	10	0.67	0.67	2.58%	129.40	21.88
Acme Solar Holdings Limited	2	4.55	4.53	5.59%	50.74	74.54
Adani Green Energy Limited	10	8.37	8.37	11.90%	101.53	76.62

Disclaimer: Above table shows earnings and P/E ratio as of 2025-26

Merchant Banker's Track Record

The two merchant bankers associated with this issue have handled 79 issues in the past three years, out of which 8 issues closed below the issue price on listing date.

Conclusion - Apply for medium to long term

QBL is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables. It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments. As the company has no listed peers, it is trying to extract fancy price for its IPO. Based on its overall financial data, the issue appears fully priced. Well-informed investors may park moderate funds for long term.

Dilip Davda is a veteran financial journalist associated with the Indian stock market since 1978. He has been contributing to print and electronic media on capital markets, insurance, and finance since 1985.

He is widely recognized for reviewing public issues and non-convertible debentures (NCDs) in the primary market. Drawing on over three decades of market experience and close interaction with merchant bankers, his reviews focus on detailed fundamental and financial analysis of companies, with a special emphasis on SME public issues.

Disclaimer: The information provided herein is solely for educational and informational purposes and does not constitute an offer, solicitation, or recommendation to buy or sell any securities. Readers are advised to consult a qualified financial advisor before making any investment decisions. Investments in the securities market are subject to market risks. The author does not intend to invest in the securities discussed.

FAQ Accordion

Q-Line Biotech IPO FAQs

1. What is Q-Line Biotech IPO? ⌄

Q-Line Biotech IPO is SME IPO. The company is going to raise ₹214 Crores via IPO. The issue is priced at ₹326 to ₹343 per equity share. The IPO is to be listed on NSE SME.

2. When Q-Line Biotech IPO will open for subscription? ⌄

The IPO is to open on May 21, 2026 for QIB, NII, and Retail Investors. The IPO will close on May 25,2026.

3. What is Q-Line Biotech IPO Investors Portion? ⌄

The investors’ portion for QIB is 50%, NII is 15%, and Retail is 35%.

4. How to Apply the Q-Line Biotech IPO? ⌄

You can apply for Q-Line Biotech IPO via ASBA online via your bank account. You can also apply for ASBA online via UPI through your stock brokers. You can also apply via your stock brokers by filling up the offline form.

5. What is Q-Line Biotech IPO Issue Size? ⌄

Q-Line Biotech IPO issue size is ₹214 crores.

6. What is Q-Line Biotech IPO Price Band? ⌄

Q-Line Biotech IPO Price Band is ₹326 to ₹343.

7. What is Q-Line Biotech IPO Lot Size? ⌄

The minimum bid is 800 Shares with ₹2,74,400 amount.

8. What is the Q-Line Biotech IPO Allotment Date? ⌄

Q-Line Biotech IPO allotment date is May 26,2026.

9. What is the Q-Line Biotech IPO Listing Date? ⌄

Q-Line Biotech IPO listing date is May 29, 2026. The IPO is to list on NSE SME.

Jaro Institute IPO Review & Investor Guide

By Jagat Joshi
September 25, 2025

Jaro Institute IPO opens on September 23, 2025, and closes on September 25, 2025. The Jaro Institute IPO price band is set between ₹846 to ₹890 per share, with a face value of ₹10 each. As per the RHP, the company plans to raise around ₹450 crores through an IPO.

For investors, it can be quite challenging to decide if the Jaro Institute IPO is a good investment or not. If you are unsure and still thinking about whether to apply or skip this IPO, don’t worry. In this article, we bring you the top important key factors and a detailed review of the Jaro Institute IPO. This will help you analyze the strengths, risks, and financial details of the Jaro Institute, making your investment decision better.

About Company

Jaro Institute is one of the growing technology-driven higher education and professional upskilling platforms. As of March 31, 2024, they have a pan-India presence with 22 offices-cum-learning centers in major cities and 15 tech studios set up in IIM campuses, serving 34 partner institutions and 239 programs and courses offered.

This company provides and delivers a broad range of online degree programs, including DBA, MBA, M.Com, M.A., PGDM, MCA, M.Sc, B.Com, and BCA. As of March 31, 2025, the company had 860 employees. Moreover, the company has high EBITDA, even though it was not taking any outside financial help, and all strong financials go to their deep experience in online higher education and upskilling.

Strengths

Jaro Institute holds a Leading position in online higher education and upskilling with a pan-India presence.
Stable revenue backed by strong and long-term client relationships across sectors.
Delivering high-quality and diverse courses.
Utilizing technology and digital tools to improve client experience and grow the business.

Weaknesses

If Partner Institutions start promoting their programs directly, it can affect their business.
The company smoothly runs its business with the dependency of the Chairman and Managing Director, senior management, and its ability to retain and attract employees. If it fails to retain or attract new ones, it can badly affect the overall business.
The number of working capital days has grown from 155 to 227.
Jaro Institute mostly generates its revenue from a few Partner Institutions, meaning losing any of them could adversely impact the overall business.

Jaro Institute IPO Review

Reviewer	Recommendation
IPO Watch	May Apply
Adroit Financial Services Private Limited	Apply
Anand Rathi	Apply
Axis Capital	Not Rated
BP Equities (BP Wealth)	Apply
Canara Bank Securities Ltd	Apply
Capital Market	Neutral
DRChoksey FinServ Pvt Ltd.	Apply
Nirmal Bang	Apply
SBICAP Securities Limited	Apply
Ventura Securities Limited	Apply

Jaro Institute IPO Details

IPO Open Date:	September 23, 2025
IPO Close Date:	September 25, 2025
Face Value:	₹10 Per Equity Share
IPO Price Band:	₹846 to ₹890 Per Share
Issue Size:	Approx ₹450 Crores
Fresh Issue:	Approx ₹170 Crores
Registrar	Bigshare Services Pvt. Ltd.
IPO Lead Managers	Nuvama Wealth Management Ltd. Motilal Oswal Investment Advisors Ltd. Systematix Corporate Services Ltd.
Basis of Allotment	September 26, 2025
IPO Listing Date:	September 30, 2025
Listing	BSE, NSE

Financial Performance Trend Details

Particulars	Fiscal 2025	Fiscal 2024	Fiscal 2023
Total Income	₹254.02 Cr	₹202.57 Cr	₹124.59 Cr
EBITDA	₹83.58 Cr	₹63.56 Cr	₹25.55 Cr
EBITDA Margin (%)	33.13%	31.93%	20.92%
Net Profit after Tax	₹51.67 Cr	₹37.97 Cr	₹11.65 Cr
Net Worth	₹171.55 Cr	₹117.43 Cr	₹77.85 Cr
Return on Capital Employed	37.38%	40.90%	19.12%
Debt-Equity Ratio	0.30	0.21	0.45
Total Borrowings	51.11	24.85	37.77

Key Indicators

KPI	Values
ROE	35.76%
ROCE	37.38%
Debt/Equity	0.30
RoNW	30.12%
PAT Margin	20.34%

Promoters & Track Records, if any

Sanjay Namdeo Salunkhe, aged 62 years, is the Chairman and Managing Director of the Company, holds 14,482,035 equity shares in the company, representing 70.98% of the paid-up Equity shares.

Balkrishna Namdeo Salunkhe, aged 58 years, is the non-executive director of the Company, holds 457,098 equity shares in the company, representing 2.24% of paid-up Equity Shares.

Expansion

Some funds will be utilized for the repayment/prepayment of certain borrowings taken by the company.
The proceeds from the new issue will be used for marketing, brand building, and advertising activities.
Lastly, the remaining funds will be utilized for the company’s general corporate purposes.

Jaro Institute IPO – Should You Apply or Not?

The fast-growing online higher education and upskilling sector backs Jaro Institute IPO. Over the years, the company has shown healthy return ratios, consistent financial growth, and strong profitability. However, Employee dependence, premium valuation, and High dependence on a few partner institutions are some risks investors must keep in mind before subscribing.

As of September 21, the GMP of the Jaro Institute is ₹104 with a price band of ₹890, representing a potential listing gain of 9%-12%.

As the IPO is priced at a higher price, the long-term investors who believe in the growth of India’s edtech and higher education space could think about subscribing. Listing gains based on GMP trends and market sentiment may be beneficial for short-term investors.

Please note:

Investors are advised to make their own decisions and apply entirely at their own risk. This article is written using information from the company’s RHP (Red Herring Prospectus) data and online sources. If you have any queries, kindly contact the IPO Watch Team.

Jagat Joshi

Founder of IPOWatch, brings nearly 15 years of experience in IPO analysis and market research. He provides complete coverage of upcoming IPOs, subscription trends, grey market premiums (GMP), and post-listing performance, along with easy-to-understand reviews, insights, and analysis. In his working journey, he has worked with various platforms and received expertise in stock market analysis and primary markets.